Back

Amgen’s Repatha sales jump 37% as Cramer flags cardiovascular opportunity

Verifying
  • Jim Cramer identified Amgen’s Repatha as an overlooked catalyst for the company’s 2026 rally.
  • Repatha generated $953 million in second-quarter sales, up 37% year over year.
  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after prescription growth accelerated.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.